NEW YORK (GenomeWeb News) — Fisher HealthCare, a division of Thermo Fisher Scientific, and Luminex will use Luminex’s xMAP instruments and assays to jointly identify molecular diagnostic applications, Luminex said today.  
 
Luminex, which develop and manufacture resulting products, said that by granting Fisher the US rights to its xMAP technology it gains a sales avenue through Fisher’s sales teams, its “access to key clinical accounts,” and its “extensive logistics network.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.